Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma gives an overview of treatment options for patients with acute myeloid leukemia (AML). 

AML is an aggressive rare cancer of the blood and bone marrow with a 5-year survival rate of only 28%. As Dr. Krivoshik mentions, traditional treatment for AML usually involves high-dose chemotherapy. However, Dr. Krivoshik warns that patients often experience a relapse or be refractory to treatment. 

Dr. Krivoshik also calls for more genetic tests in order to determine genetic factors of AML that may help in developing targeted therapies for these patients.

For more information about AML and other rare cancers, visit